Retatrutide 10 mg – Research-Grade Peptide
Product Summary
Content: 10 mg lyophilized Retatrutide peptide
Purity: ≥ 99%
Peptide Class: Triple Hormone Receptor Agonist (GLP-1, GIP, Glucagon)
Molecular Formula: C₁₉₀H₂₉₁N₄₅O₅₉
Molecular Weight: Approximately 4731.3 g/mol
Intended Use: For laboratory and research use only
Origin: Synthetic peptide developed to simultaneously activate GLP-1, GIP, and glucagon receptors
______________
What is Retatrutide?
Retatrutide is a next-generation investigational peptide designed to activate three key metabolic pathways through agonism of the GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and glucagon receptors.
This triple-receptor mechanism differentiates Retatrutide from earlier incretin-based compounds that target only one or two pathways. Through its combined metabolic activity, Retatrutide has become an important subject of research in obesity, body composition, energy expenditure, glucose regulation, and metabolic health.
Its unique pharmacological profile has attracted significant attention within the scientific community due to the substantial effects observed in clinical and preclinical metabolic research.
______________
Potential Benefits in Research
Body Weight and Adiposity Research
Retatrutide has been extensively investigated for its effects on body weight regulation and fat mass reduction through multiple complementary metabolic pathways.
Appetite Regulation
Activation of GLP-1 and GIP receptors has been associated with reduced food intake, altered satiety signaling, and appetite modulation in research settings.
Energy Expenditure Studies
The glucagon receptor component may contribute to increased energy expenditure and enhanced metabolic activity, making Retatrutide unique among incretin-based peptides.
Metabolic Health Research
Researchers are investigating Retatrutide's effects on:
• Glucose metabolism
• Insulin sensitivity
• Lipid metabolism
• Hepatic fat accumulation
• Cardiometabolic biomarkers
Body Composition Research
Studies suggest potential effects on both fat mass reduction and preservation of lean body mass during weight management interventions.
Triple-Receptor Mechanism
The simultaneous activation of GLP-1, GIP, and glucagon receptors represents a novel therapeutic strategy for addressing multiple aspects of metabolic dysfunction through a single peptide molecule.
______________
Scientific Interest and Research Applications
Retatrutide is currently being investigated in research related to:
• Obesity and weight management
• Metabolic syndrome
• Type 2 diabetes mechanisms
• Non-alcoholic fatty liver disease (NAFLD)
• Energy balance regulation
• Appetite and satiety pathways
• Cardiometabolic risk factors
• Advanced incretin biology
______________
Legal Notice and Usage Disclaimer
For Research Use Only
Retatrutide is intended strictly for laboratory research, analytical testing, and scientific investigation. It is not approved for human consumption.
Regulatory Status
Retatrutide remains an investigational compound and has not received regulatory approval for general medical use. Any research involving this peptide must comply with applicable local regulations and institutional guidelines.
Medical Disclaimer
This product is not intended to diagnose, treat, cure, or prevent any disease. It is supplied exclusively for research purposes.
______________
Product Details
Packaging: 10 mg lyophilized powder in a sterile glass vial
Storage: Store refrigerated at 2–8°C. Protect from light and moisture.
Solubility: Soluble in bacteriostatic water and appropriate sterile laboratory solvents
Appearance: White to off-white lyophilized powder
Stability: Best utilized shortly after reconstitution under controlled laboratory conditions
